Vaxart, Inc.

NASDAQ:VXRT

Biotechnology

Healthcare
$0.53 -1.75%

-$0.01 today

Market cap
$129.30M
Beta
1.09
P/E (TTM)
3.6
EPS (TTM)
$0.15
52W Low $0.26High $0.84

Volume 0.12M

Average 0.41M

VXRT Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Vaxart, Inc.NASDAQ: VXRT

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $39.23M rose 87.9% year over year, behind the +439.3% change in trailing-twelve-month gross profit. Sequentially, it fell 62.4% from the prior quarter. Over 3 fiscal years it compounded at +1204.0% a year.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +87.9% toward the trailing-twelve-month pace of +439.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$39.23M-62.4% QoQ
Last fiscal yearDec 2025
$237.26M+726.7% YoY
LTMMar 2026
$255.61M+439.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+87.9%——
1 year+726.7%——
3-year CAGR+1204.0%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
237.26M USD
Year-over-year change
+726.7%

Gross Profit vs competitors

How VXRT compares with its peers on the latest reported figures

  • VXRT's LTM Mar 2026 gross profit of $255.61M is the highest of the 10 companies compared; the peer median is $228K.
  • Its year-over-year change of +439.3% is the highest of 8, against a peer median of +82.3%.
  • Gross profit amounts to 100.0% of revenue for VXRT, versus a peer median of 74.1%.
VXRT Competitors Peer median
Gross Profit for VXRT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$255.61M +439.3%+1204.0%100.0%
FBIOFortress Biotech, Inc.LTM Mar 2026$42.68M +20.7%-2.0%64.5%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$8.44M +91.0%-18.0%92.4%
CBUSCibus, Inc.LTM Mar 2026$3.09M +2.4%—72.1%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$3M +337.0%—76.2%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$228K +137.1%——
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 ———
IMUXImmunic, Inc.LTM Mar 2026-$33K +50.0%——
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026-$66K +82.3%——
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$211K ———
Peer median (excluding VXRT) $228K+82.3%-10.0%74.1%

Competitors are the stored peer set for VXRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue892K107K7.38M28.7M237.26M
Cost of Revenue48.75M04.5M00
Gross Profit(47.86M)107K2.88M28.7M237.26M
Gross Margin-5365.1%100.0%39.0%100.0%100.0%
Research & Development48.75M81.05M68.14M74.21M201.58M
Selling, General & Admin21.89M29.39M22.58M20.78M17.61M
Operating Expenses24.9M114.69M86.23M94.99M219.18M
Depreciation & Amortization2.43M5.81M8.62M8.85M8.58M
EBITDA(66.45M)(100.58M)(72.13M)(54.87M)28.21M
EBITDA Margin-7449.7%-94000.9%-977.5%-191.2%11.9%
Operating Income(72.75M)(114.59M)(83.35M)(66.29M)18.07M
Operating Margin-8156.1%-107090.7%-1129.5%-231.0%7.6%
Interest Income81K1.25M2.65M2.54M1.6M
Interest Expense1.48M1.31M1.45M2.97M2.82M
Other Income / Expenses2.39M6.9M1.14M(395K)(1.27M)
Income Before Tax(70.36M)(107.69M)(82.2M)(66.69M)16.8M
Pre-Tax Margin-7888.2%-100645.8%-1114.0%-232.4%7.1%
Income Tax Expense107K67K261K260K476K
Net Income(70.47M)(107.76M)(82.47M)(66.95M)16.33M
Net Margin-7900.2%-100708.4%-1117.6%-233.3%6.9%
EPS (Basic)(0.14)(0.22)(0.17)(0.14)0.07
EPS (Diluted)(0.14)(0.22)(0.17)(0.14)0.07
Weighted Avg Shares487.26M487.26M487.26M487.26M230.27M
Weighted Avg Shares (Diluted)487.26M487.26M487.26M487.26M230.35M

Vaxart, Inc.

NASDAQ:VXRT

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.